Scientists at Ez Bioxcel Solutions Pvt Ltd., Invea Therapeutics Inc. and Inveniai LLC have identified apoptosis-associated speck-like protein containing a CARD (PYCARD; ASC) inhibitors reported to be useful for the treatment of primary sclerosing cholangitis, arthritis and inflammatory disorders.
Recurium IP Holdings LLC has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) binding moiety covalently linked to a Wee1-like protein kinase (Wee1)-targeting moiety via a linker reported to be useful for the treatment of cancer.
Vanderbilt University has disclosed mGlu5 receptor negative allosteric modulators reported to be useful for the treatment of anxiety, autism spectrum disorders, diabetes, pain, Parkinson’s disease, multiple sclerosis, depression and obesity, among others.
Vanqua Bio Inc. has divulged C5a anaphylatoxin chemotactic receptor 1 (C5aR; CD88) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections and cardiovascular, inflammatory and neurological disorders.
Benevolentai Cambridge Ltd. has synthesized retinoid acid receptor α (RARα) and β (RARβ) agonists reported to be useful for the treatment of cancer and amyotrophic lateral sclerosis (ALS).
Global Health Drug Discovery Institute has disclosed N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of cancer and viral infections.
Prelude Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety. They are described as potentially useful for the treatment of cancer.
RSS